Publikasi Scopus FKUI Tahun 2010 s/d 2020 (data Per 3 Februari 2021)

Arozal W., Watanabe K., Veeraveedu P.T., Thandavarayan R.A., Harima M., Sukumaran V., Suzuki K., Kodama M., Aizawa Y.
32067462200;55492737200;12796732500;23390800400;34971238300;35070365600;55624483910;7403312707;36051317800;
Effect of telmisartan in limiting the cardiotoxic effect of daunorubicin in rats
2010
Journal of Pharmacy and Pharmacology
62
12
1776
1783
23
Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata City, Japan; Department of Pharmacology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Department of Gastroenterology and Hepatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata City, Japan; First Department of Internal Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata City, Japan
Arozal, W., Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata City, Japan, Department of Pharmacology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Watanabe, K., Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata City, Japan; Veeraveedu, P.T., Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata City, Japan; Thandavarayan, R.A., Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata City, Japan; Harima, M., Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata City, Japan; Sukumaran, V., Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata City, Japan; Suzuki, K., Department of Gastroenterology and Hepatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata City, Japan; Kodama, M., First Department of Internal Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata City, Japan; Aizawa, Y., First Department of Internal Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata City, Japan
Objectives Studies have suggested that angiotensin receptor blockers may exert a protective role towards doxorubicin-induced cardiotoxicity, but they have not been extensively investigated in this area. We therefore investigated whether the co-treatment of telmisartan, an angiotensin (Ang II) type-1 receptor blocker, might offer protection against daunorubicin cardiotoxic properties in rats. Methods Daunorubicin was administered at 3mg/kg/day every other day for 12 days. Telmisartan was administered orally every day for 12 days. Key findings Daunorubicin-treated rats showed cardiac toxicity, evidenced by worsening cardiac function, evaluated by haemodynamic status and echocardiography, elevation of malondialdehyde level and a decreased level of total glutathione peroxidase activity in the heart tissue. These changes were reversed by treatment with telmisartan. Furthermore, telmisartan also downregulated matrix metalloproteinase-2 expression, attenuated the increased protein expression of p22phox, p47phox, p67phox, nuclear factor kappa B and Nox4 in heart tissue, and reduced oxidative-stress-induced DNA damage, which was evaluated by the expression of 8-hydroxydeoxyguanosine. Moreover, telmisartan reduced the myocardial apoptosis induced by daunorubicin. Conclusions The present study indicates that telmisartan may improve cardiac function by inhibiting the action of Ang II via AT-1R, which reverses oxidative stress and myocardial apoptosis. This suggests a beneficial effect of telmisartan treatment in the prevention of daunorubicin-induced cardiotoxicity. © 2010 The Authors. JPP © 2010 Royal Pharmaceutical Society of Great Britain.
Angiotensin II; Cardiotoxicity; Daunorubicin; Oxidative stress; Telmisartan
8 hydroxydeoxyguanosine; angiotensin 1 receptor; daunorubicin; gelatinase A; glutathione peroxidase; immunoglobulin enhancer binding protein; malonaldehyde; protein p22; protein p47; protein p67; reduced nicotinamide adenine dinucleotide phosphate oxidase 4; telmisartan; animal experiment; animal model; apoptosis; article; cardiotoxicity; controlled study; DNA damage; down regulation; drug effect; enzyme activity; heart function; heart protection; hemodynamics; male; nonhuman; oxidative stress; protein expression; rat; Angiotensin II Type 1 Receptor Blockers; Animals; Antibiotics, Antineoplastic; Apoptosis; Benzimidazoles; Benzoates; Daunorubicin; Doxorubicin; Heart; Heart Diseases; Male; Malondialdehyde; Matrix Metalloproteinase 2; Myocardium; Oxidative Stress; Rats; Rats, Sprague-Dawley;
00223573
JPPMA
21054405
Article
Q1